Form 4: Arcutis Biotherapeutics CEO Sells Shares to Cover Tax Obligations

Arcutis Biotherapeutics CEO Todd Franklin Watanabe sold 14,903 shares of common stock on March 4, 2024, to satisfy tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On March 4, 2024, Todd Franklin Watanabe, the President and CEO of Arcutis Biotherapeutics, sold 14,903 shares of the company's common stock.
• The sale was executed at a weighted average price of $11.1212 per share, with individual trades ranging from $11.000 to $11.3200.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
• Following the transaction, Watanabe directly owns 874,533 shares of Arcutis Biotherapeutics common stock.
• Watanabe also has indirect ownership through several trusts and an LLC, but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale to cover tax obligations and doesn't reflect a change in the executive's overall confidence in the company.

Industry Context

This is a routine transaction for executives to cover tax obligations when stock options or restricted stock units vest. It is a common practice and doesn't necessarily indicate a negative outlook on the company.

Stakeholder Impact

• The sale could have a minor impact on shareholders due to the slight dilution of shares, but it is unlikely to be significant.

Key Dates